权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of fibrosis in post-surgical lymphedema

术后淋巴水肿纤维化的机制

基本信息

批准号：
10063531
负责人：
Babak J Mehrara
金额：
$ 89.73万
依托单位：
SLOAN-KETTERING INST CAN RESEARCH
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-01 至 2022-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10063531
关键词：
Animal Model Animals Antigens Award Axillary Lymph Node Dissection B-Lymphocytes Bacterial Antigens Biopsy Specimen CD4 Positive T Lymphocytes Cell Differentiation process Cells Chronic Clinical Clone Cells Dendritic Cells Development Disease Disease Progression Estrogens Event Extracellular Matrix Female Fibrosis Formulation Functional disorder Generations Goals Immune Response Genes Immune response Immunity Immunology Impairment In Vitro Inflammation Inflammatory Inflammatory Response Injury Knockout Mice Knowledge Lead Lymphangiogenesis Lymphatic Lymphatic Endothelial Cells Lymphatic System Lymphatic function Lymphedema Mastectomy Mediating Mission Modeling Neoplasm Metastasis Nitric Oxide Nitrogen Operative Surgical Procedures Oxidative Stress Oxygen Pathologic Pathology Patients Pharmaceutical Preparations Pharmacology Play Podoconiosis Positioning Attribute Prevention strategy Process Publications Publishing Reaction Research Risk Role Sampling Secondary to Severities Signal Transduction Single Nucleotide Polymorphism Skin Source Specimen Surgical Injuries T cell receptor repertoire sequencing T cell response T-Lymphocyte Testing Tissues Topical application Transforming Growth Factor beta Transgenic Animals Translating United States National Institutes of Health Work autoreactive T cell base bench to bedside cancer cell cancer complication cancer therapy cardiovascular injury chemokine clinical practice clinically relevant cytokine design efficacy study event cycle first-in-human genome wide association study high risk immunotherapy trials innovation investigator-initiated trial keratinocyte lipid metabolism lymphatic dysfunction lymphatic vasculature lymphatic vessel macrophage male migration mouse model multidisciplinary neutralizing antibody novel novel therapeutics palliative pre-clinical prevent repaired response secondary lymphedema skin disorder small molecule inhibitor therapy development treatment strategy tumor

项目摘要

Project Summary This proposal is significant because we aim to develop novel treatments for secondary lymphedema, a common and morbid complication of cancer treatment. This is important because current therapies for this disease are palliative and inadequate. In our previous studies, we have shown that the pathology of lymphedema is secondary to progressive fibrosis and is mediated by chronic T-helper (CD4+) cell inflammation and T-helper 2 (Th2) differentiation. We have used this information to develop novel therapies for the treatment of secondary lymphedema and have recently translated our work from the bench to the bedside in an investigator-initiated trial using Th2 cytokine neutralizing antibodies. The objective of this application is to identify the cellular mechanisms that initiate CD4+ cell inflammatory responses following lymphatic injury. This objective is a logical extension of our previous work and should identify additional targets that can be targeted pharmacologically to treat/prevent lymphedema. Our long-term objective is to use the information we gain from this basic understanding of lymphedema to develop therapies that disrupt the cycle of events that promote progressive fibrosis and lymphatic dysfunction. Our approach is innovative since we use a combination of mouse models and clinical specimens to dissect the cellular mechanisms of lymphedema pathology. Our group is uniquely positioned to accomplish our goals on the basis of our multidisciplinary team, our access to clinical tissues, and our novel mouse models. We plan to achieve our objectives using 2 specific aims: Aim 1. Determine how lymphatic injury activates CD4+ cells. This aim will use clinical samples and mouse models to test the hypothesis that keratinocytes play a key role in the activation and migration of CD4+ cells to lymphedematous tissues. In addition, we will test the hypothesis that single nucleotide polymorphisms in immune response genes will increase the risk of lymphedema. Aim 3. Determine how inflammation impairs lymphatic function. This aim will test the hypothesis that inflammatory responses in lymphedema impair lymphatic function by multiple effects, including tissue and lymphatic fibrosis, perilymphatic inflammation, and impaired formation of collateral lymphatic vessels.

项目总结

项目成果

期刊论文数量（57）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

A Prospective Study on the Safety and Efficacy of Vascularized Lymph Node Transplant.

一项关于血管化淋巴结移植的安全性和有效性的前瞻性研究。

DOI：
10.1097/sla.0000000000005591
发表时间：
2022-10-01
期刊：
Annals of surgery
影响因子：
9
作者：
通讯作者：

Lymphatic Function Regulates Contact Hypersensitivity Dermatitis in Obesity.

DOI：
10.1038/jid.2015.283
发表时间：
2015-11
期刊：
The Journal of investigative dermatology
影响因子：
0
作者：
Savetsky IL;Albano NJ;Cuzzone DA;Gardenier JC;Torrisi JS;García Nores GD;Nitti MD;Hespe GE;Nelson TS;Kataru RP;Dixon JB;Mehrara BJ
通讯作者：
Mehrara BJ

Tissue-engineered lymphatic graft for the treatment of lymphedema.

用于治疗淋巴水肿的组织工程淋巴移植物。

DOI：
10.1016/j.jss.2014.07.059
发表时间：
2014
期刊：
The Journal of surgical research
影响因子：
0
作者：
Kanapathy,Muholan;Patel,NikhilM;Kalaskar,DeepakM;Mosahebi,Afshin;Mehrara,BabakJ;Seifalian,AlexanderM
通讯作者：
Seifalian,AlexanderM

Lymphedema and obesity: is there a link?

淋巴水肿和肥胖症：是否有联系？